← All diseases Cancer

Prostate cancer (metastatic)

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchEvidence of highest quality only (136)Meta-analysis (28)Treatment guideline (1)Randomized trial (67)Systematic review (20)Phase 3 study (20)Clinical trial (632)Review article (236)Early study (phase 1 or 2) (38)Single patient description (132)Laboratory or animal study (27)Commentary or editorial (29)Retracted publication (3) Studies currently seeking participants only (40)

Filter

Publications and studies (2069)

• Clinical and economic outcomes of cabazitaxel versus Lu-PSMA in mCRPC: a US perspective. (2026/12/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Extremely Rare Prostate Metastasis From Rectal Carcinoma Detected on ⁶⁸Ga-FAPI PET/CT. (2026/09/01) ♡
• How low do you need to go? Association between various prostate-specific antigen response measures and clinical outcomes in metastatic castration-sensitive prostate cancer in the Veterans Health Administration data. (2026/08/15) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Circulating microbial metabolites and the gut-prostate axis in prostate cancer: Implications for laboratory biomarkers and therapeutic response. (2026/08/15) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Design, Synthesis, and In Vitro Evaluation of a PSMA-Targeted Doxorubicin Conjugate. (2026/08/14) ♡
• Penile Metastasis From Castration-Resistant Prostate Cancer: A Case Report. (2026/08/09) ♡
• Commentary on "matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC". (2026/08/08) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Efficacy, safety, and quality of life outcomes of [(177)Lu] Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer: a GRADE-assessed systematic review, meta-analysis and trial sequential analysis. (2026/08/08) ♡
• Time-restricted eating to entrain circadian rhythms, increase physiological responsiveness, and prevent stressor-induced frailty: A pilot randomized controlled trial. (2026/08/08) ♡
• Saline-assisted Fascial Exposure Microultrasound-guided Nerve Preservation During Robotic Prostatectomy: Interim Analysis of a Randomized Controlled Trial. (2026/08/08) ♡
• Prognostic impact of regional lymph node metastasis at castration-resistant prostate cancer diagnosis on survival after radium-223 treatment. (2026/08/07) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Preclinical evaluation of itraconazole in docetaxel-resistant prostate cancer xenograft models. (2026/08/07) ♡
• Detection and Localization of Unfavorable-histology Prostate Cancer Using MRI and Whole-mount Histopathology. (2026/08/07) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Re: Armstrong AJ, Petrylak DP, Shore ND, et al. ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients. Eur Urol 2026. In press. http://dx.doi.org/10.1016/j.eururo.2025.12.021. (2026/08/07) ♡
• Predicting long-term metastatic risk after radical prostatectomy: Adding Genomic Prostate Score, grade group, and cribriform size to unfavorable histology burden translates into minimal incremental discrimination. (2026/08/07) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Impact of PSA Nadir on Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-analysis. (2026/08/07) ♡
• Prostate Cancer Recurrence Mimicking a Primary Paranasal Sinus Tumor on (18)F-FDG PET/CT During Treatment for Metastases After 10 Years of Remission. (2026/08/07) ♡
• Prognostic clinical indicators in patients with metastatic castration-resistant prostate cancer treated with radium-223 plus enzalutamide: Data from patients in J-RAP-BSI trial. (2026/08/06) ♡
• Mathematical Biomarkers of Adaptive Therapy Outcomes in Prostate Cancer. (2026/08/06) ♡
• Deep learning-based histologic classifiers enable molecular subtyping of metastatic prostate cancer. (2026/08/06) ♡
• Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4. (2026/08/06) ♡
• [(177)Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial. (2026/08/06) ♡
• [(177)Lu]Lu-PSMA-617 in metastatic androgen pathway modulator-sensitive prostate cancer. (2026/08/06) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Targeting the extracellular vesicle-immune axis in prostate cancer: mechanisms of immune evasion and emerging therapeutic strategies. (2026/08/06) ♡
• Hematologic Consequences of Radiopharmaceutical Therapy: From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms. (2026/08/06) ♡
• Real-World Outcomes of [(177)Lu]Lu-PSMA-617 in the French Early-Access Program for Patients with Metastatic Castration-Resistant Prostate Cancer. (2026/08/06) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. From fungus fighter to cancer slayer: itraconazole as a multifaceted candidate for drug-resistant prostate cancer. (2026/08/06) ♡
• Lutetium-177-PSMA-617 in Oligo-metastatic Hormone-sensitive Prostate Cancer (BULLSEYE): A Trial Update. (2026/08/05) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. EORTC 2238 DE-ESCALATE: Revisiting Intermittent Maximal Androgen Blockade in Metastatic Hormone-sensitive Prostate Cancer. (2026/08/05) ♡
• Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer. (2026/08/05) ♡
• Online adaptive radiotherapy in pelvic and thoracic cancers - comparing toxicities, clinical outcomes and technical parameters between conventional image-guided radiotherapy and online adaptive radiotherapy - the study protocol for the prospective, registry-based cohort study (PRoART). (2026/08/05) ♡
• Pleomorphic Giant Cell Carcinoma of the Prostate Treated With Lutetium-177 PSMA. (2026/08/05) ♡
• Germline genetic risk and prostate cancer-specific mortality in a population-based incident cohort. (2026/08/04) ♡
• Effectiveness and safety of hormonal doublet therapy in metastatic hormone-sensitive prostate cancer: A multicenter real-world study. (2026/08/04) ♡
• Fluid shear stress as a co-stimulatory cue to enhance T cell priming and restore activation in cancer patient T cells. (2026/08/04) ♡
• Mortality in Medicare-aged Men with Metastatic Prostate Cancer After the Introduction of Androgen Receptor Pathway Inhibitors: A Population-Based Study. (2026/08/04) ♡
• Comprehensive In Silico Analysis of the CXCL12, C55Y Mutation Reveals Structural and Functional Disruption in CXCR4/CXCR7 Signaling. (2026/08/04) ♡
• Real-world treatment of oligometastatic hormone-sensitive prostate cancer: impact of androgen receptor pathway inhibitors, metastasis-directed therapy and primary tumor radiotherapy on survival. (2026/08/03) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Beyond androgen deprivation therapy: Next-generation hormonal therapies and emerging combination approaches in advanced prostate cancer. (2026/08/03) ♡
• Biophysical insights into interaction mechanism of cediranib with human serum albumin: In-vitro and in-silico perspectives. (2026/08/03) ♡
• Clinical Impact of Gleason Pattern 5 on Doublet Versus Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer. (2026/08/02) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Treatment of Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy. (2026/08/02) ♡
• Mediation analysis of adherence to pelvic floor muscle training and weekly self-monitoring on urinary symptoms in men with localized prostate cancer A secondary analysis of the Prostate Cancer-Patient Empowerment Program (PC-PEP) randomized controlled trial. (2026/08/01) ♡
• Transcriptome-wide association studies implicate RCC1 and PHACTR4 in prostate cancer survival. (2026/08/01) ♡
• Full-Component Chart-Derived Lee Score, Upfront Androgen Receptor Signaling Inhibitor Selection, and Competing Mortality in Metastatic Hormone-Sensitive Prostate Cancer. (2026/08/01) ♡
• [(18)F]PSMA-1007 PET-Based Recurrence Site Distribution and Predictors of Metastatic Disease in Patients With Biochemical Recurrence of Prostate Cancer. (2026/08/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Comment on "Olaparib combined with abiraterone in HRR-mutated metastatic hormone-sensitive prostate cancer: a single-arm phase II trial". (2026/08/01) ♡
• Real-World Outcomes of Radium-223 Therapy in Metastatic Castration-Resistant Prostate Cancer: Predictive Value of PSA Doubling Time and Enzalutamide Continuation. (2026/08/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Real-World Outcomes of Olaparib Treatment in Japanese Patients With Metastatic Castration-Resistant Prostate Cancer Harboring BRCA Pathogenic or Likely Pathogenic Variants. (2026/08/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Transverse Versus Vertical Camera Port Incision for Patient Satisfaction After Robot-Assisted Radical Prostatectomy. (2026/08/01) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.